keyword
MENU ▼
Read by QxMD icon Read
search

oxybate

keyword
https://www.readbyqxmd.com/read/27865546/french-consensus-management-of-patients-with-hypersomnia-which-strategy
#1
R Lopez, I Arnulf, X Drouot, M Lecendreux, Y Dauvilliers
Central hypersomnias principally involves type 1 narcolepsy (NT1), type 2 narcolepsy (NT2) and idiopathic hypersomnia (IH). Despite great progress made in understanding the physiopathology of NT1 with low cerebrospinal fluid hypocretin-1 levels, current treatment remains symptomatic. The same applies to NT2 and IH, for which the physiopathology is still largely unknown. Controlling excessive daytime sleepiness (EDS), cataplexy, hypnagogic hallucinations, sleep paralysis and disturbed night-time sleep are key therapeutic targets in NT1...
November 16, 2016: Revue Neurologique
https://www.readbyqxmd.com/read/27810187/impact-of-sodium-oxybate-modafinil-and-combination-treatment-on-excessive-daytime-sleepiness-in-patients-who-have-narcolepsy-with-or-without-cataplexy
#2
Jed Black, Todd Swick, Richard Bogan, Chinglin Lai, Lawrence P Carter
BACKGROUND: Effects of sodium oxybate (SXB) on patients with narcolepsy with cataplexy (NC) or without cataplexy (NWOC) have not been separately evaluated in clinical trials. METHODS: Retrospective analysis evaluated data from a phase 3, randomized, placebo-controlled trial of SXB, modafinil, and SXB + modafinil versus placebo in adult NC patients (n = 95) or NWOC patients (n = 127). NC patients were identified based on medical history, concomitant medications, and sleep-onset REM periods on nocturnal polysomnography...
August 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27808415/an-open-label-study-of-sodium-oxybate-in-spasmodic-dysphonia
#3
Anna F Rumbach, Andrew Blitzer, Steven J Frucht, Kristina Simonyan
OBJECTIVES/HYPOTHESIS: Spasmodic dysphonia (SD) is a task-specific laryngeal dystonia that affects speech production. Co-occurring voice tremor (VT) often complicates the diagnosis and clinical management of SD. Treatment of SD and VT is largely limited to botulinum toxin injections into laryngeal musculature; other pharmacological options are not sufficiently developed. STUDY DESIGN: Open-label study. METHODS: We conducted an open-label study in 23 SD and 22 SD/VT patients to examine the effects of sodium oxybate (Xyrem), an oral agent with therapeutic effects similar to those of alcohol in these patients...
November 3, 2016: Laryngoscope
https://www.readbyqxmd.com/read/27807903/effect-of-sodium-oxybate-on-disrupted-nighttime-sleep-in-patients-with-narcolepsy
#4
Thomas Roth, Yves Dauvilliers, Diane Guinta, Sarah Alvarez-Horine, Efim Dynin, Jed Black
This post hoc analysis evaluated the dose-related effects of sodium oxybate on sleep continuity and nocturnal sleep quality in patients with narcolepsy-cataplexy. Polysomnography data, including shifts to Stage N1/Wake, were from a randomized, placebo-controlled trial of sodium oxybate. Patients were ≥16 years old with a diagnosis of narcolepsy including symptoms of cataplexy and excessive daytime sleepiness. Treatment was for 8 weeks with placebo or sodium oxybate 4.5, 6 or 9 g administered as two equally divided nightly doses...
November 3, 2016: Journal of Sleep Research
https://www.readbyqxmd.com/read/27807183/efficacy-of-sodium-oxybate-on-rem-sleep-behavior-disorder-in-a-patient-with-narcolepsy-type-1
#5
Geert Mayer
No abstract text is available yet for this article.
November 2, 2016: Neurology
https://www.readbyqxmd.com/read/27778193/evaluation-of-quality-of-life-in-patients-with-narcolepsy-treated-with-sodium-oxybate-use-of-the-36-item-short-form-health-survey-in-a-clinical-trial
#6
Richard Bogan, Todd Swick, Mortimer Mamelak, Ruzica Kovacevic-Ristanovic, Chinglin Lai, Jed Black, Kathleen F Villa, Jacques Montplaisir
INTRODUCTION: The present post hoc analysis was designed to evaluate health-related quality of life (HRQoL) using the 36-item Short Form Health Status Survey (SF-36) during an 8-week trial of sodium oxybate (SXB). METHODS: SF-36 was assessed in a phase 3 placebo-controlled trial in patients with narcolepsy (N = 228) randomized to placebo or SXB in doses of 4.5, 6, or 9 g nightly for 8 weeks. Changes from baseline in SF-36 (last observation carried forward) were compared between SXB and placebo, and effect sizes (ES) were estimated...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27752878/treatment-of-rem-sleep-behavior-disorder
#7
REVIEW
Youngsin Jung, Erik K St Louis
REM sleep behavior disorder (RBD) is a common parasomnia disorder affecting between 1 and 7 % of community-dwelling adults, most frequently older adults. RBD is characterized by nocturnal complex motor behavior and polysomnographic REM sleep without atonia. RBD is strongly associated with synucleinopathy neurodegeneration. The approach to RBD management is currently twofold: symptomatic treatment to prevent injury and prognostic counseling and longitudinal follow-up surveillance for phenoconversion toward overt neurodegenerative disorders...
November 2016: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/27752135/f-o-g-ring-formation-in-glycopeptide-antibiotic-biosynthesis-is-catalysed-by-oxye
#8
Madeleine Peschke, Clara Brieke, Max J Cryle
The glycopeptide antibiotics are peptide-based natural products with impressive antibiotic function that derives from their unique three-dimensional structure. Biosynthesis of the glycopeptide antibiotics centres of the combination of peptide synthesis, mediated by a non-ribosomal peptide synthetase, and the crosslinking of aromatic side chains of the peptide, mediated by the action of a cascade of Cytochrome P450s. Here, we report the first example of in vitro activity of OxyE, which catalyses the F-O-G ring formation reaction in teicoplanin biosynthesis...
October 18, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27735059/impact-of-concomitant-medications-on-obstructive-sleep-apnea
#9
I Jullian-Desayes, B Revol, E Chareyre, P Camus, C Villier, J C Borel, J L Pepin, M Joyeux-Faure
Obstructive sleep apnea (OSA) is characterized by repeated episodes of apnea and hypopnea during sleep. Little is known about the potential impact of therapy drugs on the underlying respiratory disorder. Any influence should be taken into account and appropriate action taken, including drug withdrawal if necessary. Here, we review drugs in terms of their possible impact on OSA; drugs which 1) may worsen OSA; 2) are unlikely to have an impact on OSA; 3) those for which data are scarce or contradictory, and 4) drugs with a potentially improving effect...
October 13, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27707443/growing-up-with-type-1-narcolepsy-its-anthropometric-and-endocrine-features
#10
Virginia Ponziani, Monia Gennari, Fabio Pizza, Antonio Balsamo, Filippo Bernardi, Giuseppe Plazzi
STUDY OBJECTIVES: To evaluate the effect of type 1 narcolepsy (NT1) on anthropometric and endocrine features in childhood/adolescence, focusing on patterns and correlates of weight, pubertal development, and growth in treated and untreated patients. METHODS: We collected anthropometric (height, weight, body mass index (BMI) z-scores), pubertal, metabolic, and endocrine data from 72 NT1 patients at diagnosis and all available premorbid anthropometric parameters of patients from their pediatric files (n = 30)...
September 29, 2016: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/27568803/core-body-and-skin-temperature-in-type-1-narcolepsy-in-daily-life-effects-of-sodium-oxybate-and-prediction-of-sleep-attacks
#11
Astrid van der Heide, Esther Werth, Claire E H M Donjacour, Robert H A M Reijntjes, Gert Jan Lammers, Eus J W Van Someren, Christian R Baumann, Rolf Fronczek
STUDY OBJECTIVES: Previous laboratory studies in narcolepsy patients showed altered core body and skin temperatures, which are hypothesised to be related to a disturbed sleep wake regulation. In this ambulatory study we assessed temperature profiles in normal daily life, and whether sleep attacks are heralded by changes in skin temperature. Furthermore, the effects of three months of treatment with sodium oxybate (SXB) were investigated. METHODS: Twenty-five narcolepsy patients and 15 healthy controls were included...
November 1, 2016: Sleep
https://www.readbyqxmd.com/read/27564079/efficiency-of-a-combination-of-pharmacological-treatment-and-nondrug-interventions-in-childhood-narcolepsy
#12
Ayşe Kacar Bayram, Hüseyin Per, Sevda Ismailoğullari, Mehmet Canpolat, Hakan Gumus, Murat Aksu
Objective Narcolepsy is a chronic sleep disorder characterized by excessive daytime sleepiness, cataplexy, hypnagogic and/or hypnopompic hallucinations, and sleep paralysis. It is one of the most important causes of excessive daytime sleepiness in the pediatric population. The aim of this study is to present the clinical and laboratory findings, and treatment results of pediatric patients with narcolepsy. Materials and Methods We studied five unrelated consecutive children with narcolepsy, focusing on clinical and laboratory features, the therapy and outcome over the 33-month follow-up period...
December 2016: Neuropediatrics
https://www.readbyqxmd.com/read/27549768/management-of-narcolepsy
#13
REVIEW
Lucie Barateau, Régis Lopez, Yves Dauvilliers
Narcolepsy type 1 (NT1) and type 2 (NT2) are two rare neurological diseases, classified as central disorders of hypersomnolence. The pathophysiology of NT1 is well known; it is caused by the selective destruction of hypocretin (Hcrt) neurons, by a highly suspected autoimmune process. On the contrary, little is known about NT2 etiology, sharing with NT1 somnolence and signs of dysregulation of rapid eye movement (REM) sleep, but not cataplexy. Management strategies are rather codified, at least in adults, with a lifelong treatment required in NT1, whereas no pharmacological study focused only on NT2 patients, with sometimes spontaneous improvement or disappearance of their symptoms...
October 2016: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/27538329/-management-of-central-hypersomnias
#14
Yves Dauvilliers, Régis Lopez
Central hypersomnias include narcolepsy type 1, type 2 and idiopathic hypersomnia with daytime sleepiness excessive in the foreground of the clinical symptoms. Despite major advances in our understanding of the mechanisms of the narcolepsy type 1 with a low level of hypocretin-1 in cerebrospinal fluid, its current management is only symptomatic. The current management is also only symptomatic for type 2 narcolepsy and idiopathic hypersomnia with an unknown pathophysiology. Treatment options may vary from a single drug targeting several symptoms or several drugs treating a specific symptom...
June 2016: La Revue du Praticien
https://www.readbyqxmd.com/read/27362466/recent-strategies-for-drug-development-in-fibromyalgia-syndrome
#15
David E Blumenthal, Charles J Malemud
INTRODUCTION: The US Federal Drug Administration (FDA) approved 3 medications for treating fibromyalgia syndrome (FMS). There have been no additional FDA approvals since January 2009 and the efficacy of the FDA-approved medications for FMS has been questioned. AREAS COVERED: The "search for studies" tool using clinicaltrials.gov and PubMed were employed. The term, "fibromyalgia" was used for clinicaltrials.gov. The terms employed for PubMed were "Name-of-Drug Fibromyalgia", "Fibromyalgia Treatment" or "Fibromyalgia Drug Treatment...
July 14, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27317048/judge-orders-that-teenager-with-narcolepsy-be-allowed-to-try-sodium-oxybate
#16
Clare Dyer
No abstract text is available yet for this article.
2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27155860/treatment-options-for-narcolepsy
#17
Lucie Barateau, Régis Lopez, Yves Dauvilliers
Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy absent. Despite major advances in our understanding of narcolepsy mechanisms, its current management is only symptomatic. Treatment options may vary from a single drug that targets several symptoms, or multiple medications that each treats a specific symptom...
May 2016: CNS Drugs
https://www.readbyqxmd.com/read/27153596/oxybs-estimation-of-5-methylcytosine-and-5-hydroxymethylcytosine-from-tandem-treated-oxidative-bisulfite-and-bisulfite-dna
#18
E Andres Houseman, Kevin C Johnson, Brock C Christensen
UNLABELLED: The use of sodium bisulfite (BS) treatment followed by hybridization to an Illumina Infinium BeadChip (HumanMethylation450 and MethylationEPIC) is a common method for interrogating 5-methylcytosine (5mC) at single nucleotide resolution. However, standard treatment of DNA with BS does not allow disambiguation of 5mC from an additional cytosine modification, 5-hydroxymethylcytosine (5hmC). Recently, it has been demonstrated that paired BS and oxidative bisulfite (oxBS) treatment on the same sample followed by hybridization to an Infinium microarray permits the differentiation of 5hmC from 5mC...
August 15, 2016: Bioinformatics
https://www.readbyqxmd.com/read/27126864/prescribing-sodium-oxybate-for-narcolepsy
#19
EDITORIAL
Adam Zeman, Zenobia Zaiwalla
No abstract text is available yet for this article.
2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27057786/treatment-of-narcolepsy-with-sodium-oxybate-while-breastfeeding-a-case-report
#20
Lauren Z Gashlin, David Sullo, Ruth A Lawrence, Casey Rosen-Carole
BACKGROUND: Sodium oxybate is used in the treatment of narcolepsy. Currently no published literature supports its safety during breastfeeding, although it has a favorable pharmacokinetic profile for minimizing exposure. MATERIALS AND METHODS: We report a case of a 27-year-old primigravida with narcolepsy who was taking sodium oxybate for symptom control and contacted our Lactation Study Center for advice. Based on our current pharmacokinetic knowledge, she was advised to avoid breastfeeding 4 hours after a dose...
June 2016: Breastfeeding Medicine: the Official Journal of the Academy of Breastfeeding Medicine
keyword
keyword
106169
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"